| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Macular Degeneration | 75 | 2024 | 1015 | 7.410 |
Why?
|
| Choroidal Neovascularization | 55 | 2024 | 364 | 7.030 |
Why?
|
| Photochemotherapy | 43 | 2021 | 830 | 4.330 |
Why?
|
| Porphyrins | 33 | 2014 | 352 | 3.190 |
Why?
|
| Photosensitizing Agents | 37 | 2017 | 629 | 2.940 |
Why?
|
| Retinal Detachment | 23 | 2023 | 429 | 2.930 |
Why?
|
| Fluorescein Angiography | 65 | 2024 | 1086 | 2.920 |
Why?
|
| Ophthalmology | 16 | 2024 | 560 | 2.900 |
Why?
|
| Photoreceptor Cells, Vertebrate | 17 | 2023 | 203 | 2.450 |
Why?
|
| Visual Acuity | 51 | 2024 | 2714 | 2.400 |
Why?
|
| Choroid | 26 | 2024 | 364 | 2.300 |
Why?
|
| Retinal Pigment Epithelium | 15 | 2020 | 309 | 2.120 |
Why?
|
| Vascular Endothelial Growth Factor A | 43 | 2022 | 3514 | 2.070 |
Why?
|
| Tomography, Optical Coherence | 38 | 2024 | 2957 | 1.990 |
Why?
|
| Retina | 43 | 2023 | 2662 | 1.750 |
Why?
|
| Neovascularization, Pathologic | 24 | 2019 | 2630 | 1.720 |
Why?
|
| Retinal Diseases | 14 | 2021 | 710 | 1.500 |
Why?
|
| Diabetic Retinopathy | 16 | 2024 | 1300 | 1.450 |
Why?
|
| Retinal Vessels | 21 | 2024 | 864 | 1.310 |
Why?
|
| Angiogenesis Inhibitors | 17 | 2022 | 2055 | 1.270 |
Why?
|
| Eye | 11 | 2021 | 712 | 1.250 |
Why?
|
| Glaucoma | 13 | 2024 | 1194 | 1.220 |
Why?
|
| Apoptosis | 28 | 2019 | 9521 | 1.180 |
Why?
|
| Disease Models, Animal | 48 | 2023 | 18344 | 1.050 |
Why?
|
| Laser Coagulation | 11 | 2011 | 334 | 1.010 |
Why?
|
| Endothelial Growth Factors | 15 | 2003 | 671 | 1.010 |
Why?
|
| Lymphokines | 15 | 2003 | 924 | 0.970 |
Why?
|
| Fundus Oculi | 23 | 2024 | 560 | 0.960 |
Why?
|
| Retinal Degeneration | 8 | 2023 | 414 | 0.940 |
Why?
|
| Retinal Vein Occlusion | 8 | 2021 | 149 | 0.920 |
Why?
|
| Wet Macular Degeneration | 9 | 2024 | 165 | 0.870 |
Why?
|
| Rats, Inbred BN | 16 | 2016 | 229 | 0.860 |
Why?
|
| Retinal Drusen | 6 | 2024 | 78 | 0.850 |
Why?
|
| Aminoimidazole Carboxamide | 8 | 2020 | 85 | 0.830 |
Why?
|
| Eye Infections, Bacterial | 5 | 2016 | 239 | 0.790 |
Why?
|
| Contrast Sensitivity | 5 | 2024 | 253 | 0.780 |
Why?
|
| In Situ Nick-End Labeling | 14 | 2019 | 610 | 0.770 |
Why?
|
| Eye Injuries | 4 | 2014 | 228 | 0.750 |
Why?
|
| Geographic Atrophy | 6 | 2024 | 92 | 0.740 |
Why?
|
| Caspases | 13 | 2019 | 882 | 0.730 |
Why?
|
| Chemokine CCL2 | 8 | 2011 | 605 | 0.730 |
Why?
|
| Iris | 9 | 2014 | 232 | 0.730 |
Why?
|
| Eye Diseases | 6 | 2009 | 660 | 0.720 |
Why?
|
| Retinal Artery Occlusion | 6 | 2024 | 83 | 0.690 |
Why?
|
| Photoreceptor Cells | 4 | 2023 | 234 | 0.680 |
Why?
|
| Retinal Neovascularization | 10 | 2024 | 288 | 0.680 |
Why?
|
| Cataract Extraction | 5 | 2022 | 464 | 0.660 |
Why?
|
| Registries | 17 | 2024 | 8377 | 0.650 |
Why?
|
| Dark Adaptation | 5 | 2021 | 224 | 0.630 |
Why?
|
| Capillary Permeability | 16 | 2012 | 772 | 0.610 |
Why?
|
| Macaca fascicularis | 22 | 2008 | 912 | 0.610 |
Why?
|
| Retinal Ganglion Cells | 7 | 2019 | 811 | 0.600 |
Why?
|
| Retinoschisis | 1 | 2018 | 30 | 0.600 |
Why?
|
| Sclera | 6 | 2023 | 189 | 0.580 |
Why?
|
| Ribonucleotides | 7 | 2020 | 114 | 0.560 |
Why?
|
| Vitreous Body | 14 | 2018 | 401 | 0.540 |
Why?
|
| Research Support as Topic | 1 | 2021 | 696 | 0.530 |
Why?
|
| Chlamydophila Infections | 2 | 2007 | 23 | 0.530 |
Why?
|
| Hospitalists | 1 | 2020 | 298 | 0.530 |
Why?
|
| Chlamydophila pneumoniae | 2 | 2007 | 53 | 0.520 |
Why?
|
| Retinoblastoma | 7 | 2014 | 321 | 0.520 |
Why?
|
| Cytochromes c | 2 | 2008 | 173 | 0.520 |
Why?
|
| Glucocorticoids | 4 | 2010 | 2166 | 0.510 |
Why?
|
| Uveal Neoplasms | 2 | 2016 | 344 | 0.500 |
Why?
|
| Cell Death | 10 | 2023 | 1679 | 0.490 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 6 | 2023 | 146 | 0.490 |
Why?
|
| Animals | 114 | 2023 | 169222 | 0.490 |
Why?
|
| Tumor Necrosis Factor-alpha | 11 | 2020 | 4351 | 0.470 |
Why?
|
| Caspase 9 | 4 | 2008 | 184 | 0.470 |
Why?
|
| Strabismus | 3 | 2024 | 320 | 0.460 |
Why?
|
| Corneal Neovascularization | 3 | 2019 | 184 | 0.460 |
Why?
|
| Humans | 201 | 2024 | 767991 | 0.440 |
Why?
|
| Hydroxychloroquine | 1 | 2018 | 426 | 0.440 |
Why?
|
| Rats | 29 | 2016 | 23751 | 0.440 |
Why?
|
| Intraocular Pressure | 13 | 2024 | 1304 | 0.440 |
Why?
|
| Caspase 3 | 5 | 2007 | 730 | 0.440 |
Why?
|
| Keratoplasty, Penetrating | 2 | 2024 | 143 | 0.430 |
Why?
|
| Cataract | 3 | 2023 | 837 | 0.430 |
Why?
|
| Blotting, Western | 17 | 2014 | 5024 | 0.420 |
Why?
|
| Apoptosis Inducing Factor | 2 | 2012 | 51 | 0.420 |
Why?
|
| Sentinel Surveillance | 1 | 2015 | 292 | 0.420 |
Why?
|
| Pterygium | 2 | 2023 | 24 | 0.420 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 7 | 2014 | 425 | 0.420 |
Why?
|
| Metabolomics | 6 | 2022 | 1674 | 0.410 |
Why?
|
| Uveitis, Anterior | 3 | 2011 | 103 | 0.400 |
Why?
|
| Research | 1 | 2021 | 1979 | 0.400 |
Why?
|
| Endophthalmitis | 3 | 2016 | 263 | 0.400 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2012 | 587 | 0.390 |
Why?
|
| Fibroblast Growth Factor 2 | 3 | 2019 | 590 | 0.380 |
Why?
|
| Antipyrine | 1 | 2011 | 40 | 0.380 |
Why?
|
| Antibodies, Monoclonal | 11 | 2009 | 9252 | 0.370 |
Why?
|
| Alphaherpesvirinae | 1 | 2011 | 9 | 0.370 |
Why?
|
| Macula Lutea | 2 | 2024 | 180 | 0.370 |
Why?
|
| Lipofuscin | 1 | 2010 | 40 | 0.360 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2011 | 103 | 0.360 |
Why?
|
| Graves Ophthalmopathy | 2 | 2023 | 135 | 0.360 |
Why?
|
| Eye Proteins | 5 | 2018 | 628 | 0.360 |
Why?
|
| Glaucoma Drainage Implants | 2 | 2022 | 107 | 0.350 |
Why?
|
| Free Radical Scavengers | 1 | 2011 | 213 | 0.350 |
Why?
|
| Eye Infections, Viral | 1 | 2011 | 61 | 0.350 |
Why?
|
| Refractive Surgical Procedures | 1 | 2010 | 21 | 0.340 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 16 | 2014 | 3813 | 0.340 |
Why?
|
| Male | 114 | 2024 | 364641 | 0.340 |
Why?
|
| Academic Medical Centers | 4 | 2024 | 2783 | 0.330 |
Why?
|
| Trabeculectomy | 2 | 2021 | 174 | 0.320 |
Why?
|
| Ribonucleosides | 2 | 2020 | 79 | 0.320 |
Why?
|
| Endothelium, Vascular | 10 | 2012 | 4427 | 0.320 |
Why?
|
| Herpesviridae Infections | 1 | 2011 | 269 | 0.320 |
Why?
|
| Neuroglia | 3 | 2017 | 961 | 0.320 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 6 | 2022 | 662 | 0.320 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2011 | 394 | 0.310 |
Why?
|
| Spectrometry, Fluorescence | 2 | 2010 | 695 | 0.310 |
Why?
|
| Choroid Diseases | 5 | 2018 | 63 | 0.310 |
Why?
|
| Disease Management | 1 | 2019 | 2533 | 0.310 |
Why?
|
| Fluorescence | 2 | 2010 | 757 | 0.310 |
Why?
|
| Macrophages | 10 | 2019 | 5799 | 0.300 |
Why?
|
| Vascular Endothelial Growth Factors | 15 | 2003 | 748 | 0.300 |
Why?
|
| Injections | 9 | 2009 | 840 | 0.300 |
Why?
|
| Vitreoretinopathy, Proliferative | 1 | 2009 | 75 | 0.300 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2014 | 2456 | 0.300 |
Why?
|
| Aged, 80 and over | 46 | 2024 | 59598 | 0.300 |
Why?
|
| Neoplasms, Second Primary | 1 | 2016 | 1061 | 0.300 |
Why?
|
| Biomedical Research | 2 | 2013 | 3463 | 0.290 |
Why?
|
| Specialization | 1 | 2013 | 779 | 0.290 |
Why?
|
| Uveitis | 5 | 2012 | 398 | 0.290 |
Why?
|
| Glaucoma, Open-Angle | 3 | 2022 | 742 | 0.290 |
Why?
|
| Myopia | 4 | 2021 | 254 | 0.280 |
Why?
|
| Drug Therapy, Combination | 7 | 2013 | 6314 | 0.280 |
Why?
|
| Retinal Neoplasms | 4 | 2014 | 151 | 0.280 |
Why?
|
| Fovea Centralis | 6 | 2020 | 126 | 0.280 |
Why?
|
| Mice, Inbred C57BL | 27 | 2021 | 22381 | 0.280 |
Why?
|
| Ciliary Body | 2 | 2014 | 168 | 0.280 |
Why?
|
| Retinitis | 1 | 2007 | 36 | 0.280 |
Why?
|
| Medical Errors | 1 | 2015 | 1260 | 0.270 |
Why?
|
| Aged | 73 | 2024 | 171446 | 0.270 |
Why?
|
| Retinal Perforations | 2 | 2006 | 138 | 0.270 |
Why?
|
| Cell Survival | 11 | 2018 | 5772 | 0.270 |
Why?
|
| Benzoquinones | 1 | 2007 | 198 | 0.270 |
Why?
|
| Fluorescein-5-isothiocyanate | 3 | 2005 | 221 | 0.270 |
Why?
|
| Oligonucleotides | 3 | 2004 | 563 | 0.270 |
Why?
|
| Eye Infections | 1 | 2007 | 63 | 0.270 |
Why?
|
| Vimentin | 1 | 2007 | 257 | 0.270 |
Why?
|
| Phosphotransferases (Phosphate Group Acceptor) | 2 | 2017 | 18 | 0.260 |
Why?
|
| Aptamers, Nucleotide | 3 | 2021 | 163 | 0.260 |
Why?
|
| Immunoglobulin Fragments | 2 | 2005 | 84 | 0.260 |
Why?
|
| Optic Disk | 3 | 2020 | 421 | 0.260 |
Why?
|
| Enzyme Activation | 7 | 2019 | 3587 | 0.250 |
Why?
|
| Visual Fields | 3 | 2024 | 1065 | 0.250 |
Why?
|
| HIV Protease Inhibitors | 1 | 2008 | 430 | 0.250 |
Why?
|
| Recombinant Fusion Proteins | 7 | 2022 | 3740 | 0.250 |
Why?
|
| Oligopeptides | 4 | 2019 | 1194 | 0.250 |
Why?
|
| Amino Acid Oxidoreductases | 3 | 2014 | 149 | 0.250 |
Why?
|
| Bruch Membrane | 5 | 2019 | 65 | 0.250 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2007 | 514 | 0.250 |
Why?
|
| Fusarium | 1 | 2005 | 50 | 0.250 |
Why?
|
| Mice | 42 | 2021 | 82024 | 0.250 |
Why?
|
| Lactams, Macrocyclic | 1 | 2007 | 319 | 0.250 |
Why?
|
| Blood-Retinal Barrier | 4 | 2009 | 63 | 0.240 |
Why?
|
| Ocular Hypertension | 3 | 2019 | 211 | 0.240 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2007 | 563 | 0.240 |
Why?
|
| AMP-Activated Protein Kinases | 4 | 2020 | 593 | 0.240 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2005 | 57 | 0.240 |
Why?
|
| Epigenomics | 1 | 2011 | 959 | 0.240 |
Why?
|
| Endotoxins | 4 | 2008 | 519 | 0.240 |
Why?
|
| Female | 90 | 2024 | 397113 | 0.240 |
Why?
|
| Quality Assurance, Health Care | 1 | 2015 | 2175 | 0.240 |
Why?
|
| Reactive Oxygen Species | 3 | 2011 | 2149 | 0.240 |
Why?
|
| Awards and Prizes | 2 | 2006 | 365 | 0.240 |
Why?
|
| Interleukin-8 | 4 | 2017 | 704 | 0.240 |
Why?
|
| Middle Aged | 58 | 2024 | 223422 | 0.230 |
Why?
|
| Retrospective Studies | 37 | 2024 | 81746 | 0.230 |
Why?
|
| Education, Medical, Continuing | 1 | 2010 | 829 | 0.230 |
Why?
|
| Metalloporphyrins | 2 | 2001 | 41 | 0.230 |
Why?
|
| Dexamethasone | 2 | 2011 | 1964 | 0.230 |
Why?
|
| Drug Delivery Systems | 6 | 2016 | 2230 | 0.230 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2007 | 422 | 0.230 |
Why?
|
| Aspergillus fumigatus | 1 | 2005 | 158 | 0.230 |
Why?
|
| Corneal Opacity | 1 | 2024 | 52 | 0.230 |
Why?
|
| DNA, Viral | 1 | 2011 | 2201 | 0.220 |
Why?
|
| Cross-Sectional Studies | 23 | 2024 | 26375 | 0.220 |
Why?
|
| Ophthalmia, Sympathetic | 1 | 2023 | 18 | 0.220 |
Why?
|
| Eye Infections, Fungal | 3 | 2016 | 99 | 0.220 |
Why?
|
| Necrosis | 5 | 2023 | 1616 | 0.220 |
Why?
|
| Pharmacokinetics | 1 | 2004 | 86 | 0.220 |
Why?
|
| Complement Factor H | 6 | 2011 | 110 | 0.220 |
Why?
|
| Intraoperative Complications | 2 | 2018 | 1171 | 0.220 |
Why?
|
| Aphakia | 1 | 2023 | 26 | 0.220 |
Why?
|
| Ischemia | 6 | 2003 | 1900 | 0.220 |
Why?
|
| Stress, Physiological | 1 | 2011 | 1409 | 0.220 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2017 | 423 | 0.220 |
Why?
|
| Blindness | 2 | 2023 | 587 | 0.210 |
Why?
|
| NF-kappa B | 7 | 2016 | 2493 | 0.210 |
Why?
|
| Conjunctiva | 2 | 2023 | 477 | 0.210 |
Why?
|
| Peptides, Cyclic | 1 | 2005 | 391 | 0.210 |
Why?
|
| Prospective Studies | 27 | 2024 | 54924 | 0.210 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2014 | 547 | 0.210 |
Why?
|
| Drug Therapy | 1 | 2006 | 504 | 0.210 |
Why?
|
| Bone Marrow Transplantation | 2 | 2012 | 2710 | 0.210 |
Why?
|
| Lacrimal Duct Obstruction | 1 | 2023 | 53 | 0.210 |
Why?
|
| Lens Subluxation | 1 | 2002 | 23 | 0.200 |
Why?
|
| Interleukin-1 | 1 | 2006 | 1252 | 0.200 |
Why?
|
| Visually Impaired Persons | 1 | 2023 | 79 | 0.200 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 5366 | 0.200 |
Why?
|
| Enzyme Inhibitors | 8 | 2018 | 3726 | 0.200 |
Why?
|
| Dacryocystorhinostomy | 1 | 2023 | 78 | 0.200 |
Why?
|
| Nasolacrimal Duct | 1 | 2023 | 79 | 0.200 |
Why?
|
| Mycoses | 1 | 2005 | 386 | 0.200 |
Why?
|
| Serpins | 2 | 2011 | 246 | 0.200 |
Why?
|
| Immunoglobulin G | 3 | 2012 | 4564 | 0.200 |
Why?
|
| Inflammasomes | 2 | 2019 | 540 | 0.200 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2006 | 878 | 0.200 |
Why?
|
| Lasers | 4 | 2019 | 952 | 0.190 |
Why?
|
| Academies and Institutes | 1 | 2024 | 326 | 0.190 |
Why?
|
| Keratitis, Herpetic | 1 | 2022 | 76 | 0.190 |
Why?
|
| Safety | 10 | 2005 | 1159 | 0.190 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 4 | 2018 | 252 | 0.190 |
Why?
|
| Trigeminal Nerve Diseases | 1 | 2022 | 48 | 0.190 |
Why?
|
| Empathy | 1 | 2006 | 474 | 0.190 |
Why?
|
| Photography | 5 | 2018 | 537 | 0.190 |
Why?
|
| Oxidative Stress | 5 | 2019 | 3140 | 0.190 |
Why?
|
| Microglia | 5 | 2019 | 1376 | 0.190 |
Why?
|
| Corneal Dystrophies, Hereditary | 1 | 2022 | 62 | 0.190 |
Why?
|
| Receptors, CCR2 | 2 | 2016 | 216 | 0.190 |
Why?
|
| Injections, Intraperitoneal | 4 | 2012 | 411 | 0.190 |
Why?
|
| Disease Progression | 7 | 2024 | 13665 | 0.190 |
Why?
|
| Vision, Low | 1 | 2023 | 162 | 0.190 |
Why?
|
| Cholesterol | 4 | 2017 | 2914 | 0.190 |
Why?
|
| Job Description | 1 | 2001 | 61 | 0.180 |
Why?
|
| Antifungal Agents | 2 | 2005 | 761 | 0.180 |
Why?
|
| Dextrans | 2 | 2000 | 574 | 0.180 |
Why?
|
| Vitreous Hemorrhage | 1 | 2021 | 47 | 0.180 |
Why?
|
| Nerve Growth Factors | 2 | 2011 | 564 | 0.180 |
Why?
|
| Phacoemulsification | 1 | 2002 | 151 | 0.180 |
Why?
|
| RNA, Messenger | 12 | 2019 | 12797 | 0.180 |
Why?
|
| Quinolines | 1 | 2006 | 770 | 0.180 |
Why?
|
| Intravitreal Injections | 4 | 2022 | 402 | 0.180 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 1 | 2 | 2011 | 50 | 0.180 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 9 | 2012 | 4576 | 0.180 |
Why?
|
| Plasminogen | 1 | 2000 | 144 | 0.180 |
Why?
|
| Visual Field Tests | 2 | 2022 | 415 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2018 | 10757 | 0.170 |
Why?
|
| Chlamydia Infections | 1 | 2004 | 365 | 0.170 |
Why?
|
| GTPase-Activating Proteins | 3 | 2019 | 468 | 0.170 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2024 | 238 | 0.170 |
Why?
|
| Telemedicine | 1 | 2018 | 3109 | 0.170 |
Why?
|
| Exfoliation Syndrome | 2 | 2014 | 113 | 0.170 |
Why?
|
| Melanoma | 2 | 2016 | 5706 | 0.170 |
Why?
|
| Burns, Chemical | 1 | 2021 | 123 | 0.170 |
Why?
|
| Retinal Rod Photoreceptor Cells | 1 | 2021 | 204 | 0.170 |
Why?
|
| Triazoles | 1 | 2005 | 904 | 0.170 |
Why?
|
| Lysosomal-Associated Membrane Protein 2 | 1 | 2019 | 53 | 0.170 |
Why?
|
| Vision Disorders | 4 | 2022 | 1093 | 0.170 |
Why?
|
| School Admission Criteria | 1 | 2020 | 107 | 0.170 |
Why?
|
| Polymerase Chain Reaction | 8 | 2014 | 6071 | 0.170 |
Why?
|
| Nurse's Role | 1 | 2001 | 188 | 0.170 |
Why?
|
| Risk Factors | 22 | 2023 | 74936 | 0.160 |
Why?
|
| Fatty Acids, Unsaturated | 2 | 2020 | 542 | 0.160 |
Why?
|
| Phosphorylation | 7 | 2020 | 8314 | 0.160 |
Why?
|
| Polyglycolic Acid | 2 | 2016 | 408 | 0.160 |
Why?
|
| N-Methylaspartate | 2 | 2019 | 231 | 0.160 |
Why?
|
| Dry Eye Syndromes | 1 | 2024 | 385 | 0.160 |
Why?
|
| Ciliary Arteries | 1 | 2019 | 19 | 0.160 |
Why?
|
| Bone Marrow Cells | 1 | 2006 | 2414 | 0.160 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2020 | 190 | 0.160 |
Why?
|
| Complement C3 | 1 | 2020 | 434 | 0.160 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2022 | 354 | 0.160 |
Why?
|
| Up-Regulation | 6 | 2019 | 4146 | 0.160 |
Why?
|
| Endothelial Cells | 5 | 2017 | 3589 | 0.160 |
Why?
|
| Retinal Telangiectasis | 1 | 2019 | 26 | 0.160 |
Why?
|
| Basement Membrane | 1 | 2019 | 348 | 0.160 |
Why?
|
| Leukocytes | 7 | 2017 | 2035 | 0.150 |
Why?
|
| Personnel Selection | 1 | 2020 | 201 | 0.150 |
Why?
|
| Liposomes | 6 | 2004 | 790 | 0.150 |
Why?
|
| Clinical Competence | 3 | 2020 | 4857 | 0.150 |
Why?
|
| Fluorescein | 5 | 2014 | 176 | 0.150 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2014 | 615 | 0.150 |
Why?
|
| Amine Oxidase (Copper-Containing) | 2 | 2008 | 41 | 0.150 |
Why?
|
| Antiviral Agents | 1 | 2011 | 3073 | 0.150 |
Why?
|
| Mitochondria | 2 | 2009 | 3681 | 0.150 |
Why?
|
| Complement Factor B | 1 | 2017 | 57 | 0.150 |
Why?
|
| Proteins | 4 | 2014 | 6009 | 0.150 |
Why?
|
| Healthcare Disparities | 2 | 2024 | 3414 | 0.150 |
Why?
|
| United States | 19 | 2024 | 73027 | 0.150 |
Why?
|
| Child, Preschool | 12 | 2024 | 42665 | 0.150 |
Why?
|
| Receptors, Purinergic P2Y12 | 1 | 2018 | 117 | 0.150 |
Why?
|
| Vitrectomy | 4 | 2016 | 392 | 0.140 |
Why?
|
| Rabbits | 8 | 2003 | 4771 | 0.140 |
Why?
|
| Body Fluids | 1 | 2019 | 321 | 0.140 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2007 | 2271 | 0.140 |
Why?
|
| Optic Nerve Diseases | 2 | 2017 | 342 | 0.140 |
Why?
|
| Pigment Epithelium of Eye | 4 | 2014 | 209 | 0.140 |
Why?
|
| Membrane Glycoproteins | 4 | 2012 | 3710 | 0.140 |
Why?
|
| Students, Medical | 2 | 2021 | 1963 | 0.140 |
Why?
|
| Second Messenger Systems | 1 | 2017 | 203 | 0.140 |
Why?
|
| Intercellular Adhesion Molecule-1 | 4 | 2011 | 1134 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 3 | 2013 | 7470 | 0.140 |
Why?
|
| Follow-Up Studies | 16 | 2024 | 39345 | 0.130 |
Why?
|
| Treatment Outcome | 18 | 2024 | 65364 | 0.130 |
Why?
|
| Inflammation | 5 | 2017 | 10871 | 0.130 |
Why?
|
| Phosphoproteins | 3 | 2017 | 2450 | 0.130 |
Why?
|
| Cell Cycle | 4 | 2019 | 2932 | 0.130 |
Why?
|
| Cornea | 1 | 2004 | 1316 | 0.130 |
Why?
|
| Sickness Impact Profile | 2 | 2024 | 299 | 0.130 |
Why?
|
| Microscopy, Fluorescence | 6 | 2015 | 2634 | 0.130 |
Why?
|
| Software | 2 | 2020 | 4478 | 0.130 |
Why?
|
| Polyglactin 910 | 1 | 2016 | 56 | 0.130 |
Why?
|
| Internship and Residency | 4 | 2020 | 5952 | 0.130 |
Why?
|
| Infant | 10 | 2024 | 36534 | 0.130 |
Why?
|
| Physicians | 1 | 2013 | 4598 | 0.120 |
Why?
|
| Serine Endopeptidases | 3 | 2011 | 1027 | 0.120 |
Why?
|
| Lactic Acid | 2 | 2016 | 1140 | 0.120 |
Why?
|
| Tonometry, Ocular | 2 | 2006 | 238 | 0.120 |
Why?
|
| Fisheries | 1 | 1996 | 48 | 0.120 |
Why?
|
| Adult | 31 | 2024 | 223583 | 0.120 |
Why?
|
| Complement Pathway, Alternative | 1 | 2015 | 113 | 0.120 |
Why?
|
| Optic Neuropathy, Ischemic | 1 | 2016 | 87 | 0.120 |
Why?
|
| Protein Carbonylation | 2 | 2011 | 27 | 0.120 |
Why?
|
| Serum Albumin, Bovine | 2 | 2009 | 320 | 0.120 |
Why?
|
| Comparative Effectiveness Research | 1 | 2020 | 714 | 0.120 |
Why?
|
| Adolescent | 13 | 2024 | 89155 | 0.120 |
Why?
|
| Lasers, Semiconductor | 2 | 2011 | 44 | 0.120 |
Why?
|
| Antibodies | 2 | 2018 | 2421 | 0.120 |
Why?
|
| Blood-Aqueous Barrier | 1 | 2014 | 7 | 0.120 |
Why?
|
| Immunoenzyme Techniques | 5 | 2005 | 1698 | 0.120 |
Why?
|
| Dyslipidemias | 1 | 2022 | 873 | 0.110 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2014 | 876 | 0.110 |
Why?
|
| Ambulatory Care Facilities | 1 | 2020 | 939 | 0.110 |
Why?
|
| Permeability | 3 | 2006 | 725 | 0.110 |
Why?
|
| Cell Line | 9 | 2020 | 15597 | 0.110 |
Why?
|
| Organometallic Compounds | 2 | 2002 | 648 | 0.110 |
Why?
|
| Polyesters | 1 | 2016 | 376 | 0.110 |
Why?
|
| Antioxidants | 3 | 2016 | 1674 | 0.110 |
Why?
|
| Fungi | 1 | 2016 | 345 | 0.110 |
Why?
|
| Educational Measurement | 1 | 2020 | 1260 | 0.110 |
Why?
|
| Cells, Cultured | 7 | 2020 | 19017 | 0.110 |
Why?
|
| Wounds, Penetrating | 1 | 1996 | 316 | 0.110 |
Why?
|
| Antibodies, Blocking | 2 | 2011 | 250 | 0.110 |
Why?
|
| Glaucoma, Neovascular | 2 | 2007 | 37 | 0.110 |
Why?
|
| Peroxiredoxins | 1 | 2013 | 51 | 0.110 |
Why?
|
| Child | 13 | 2024 | 80906 | 0.110 |
Why?
|
| Cell Proliferation | 9 | 2017 | 10470 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2014 | 18062 | 0.110 |
Why?
|
| Pyrimidines | 1 | 2005 | 3046 | 0.110 |
Why?
|
| Lipids | 3 | 2022 | 3342 | 0.110 |
Why?
|
| Lipid Metabolism | 2 | 2022 | 1904 | 0.110 |
Why?
|
| Food, Fortified | 1 | 2014 | 189 | 0.100 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2016 | 1168 | 0.100 |
Why?
|
| Indoles | 3 | 2019 | 1835 | 0.100 |
Why?
|
| Systems Biology | 2 | 2019 | 482 | 0.100 |
Why?
|
| Hyaluronic Acid | 2 | 2013 | 484 | 0.100 |
Why?
|
| Macrophage Activation | 1 | 2016 | 557 | 0.100 |
Why?
|
| Rats, Long-Evans | 3 | 2009 | 380 | 0.100 |
Why?
|
| Immunoblotting | 6 | 2014 | 1647 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2011 | 16041 | 0.100 |
Why?
|
| Pediatrics | 1 | 2008 | 3629 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2013 | 145 | 0.100 |
Why?
|
| Postoperative Complications | 6 | 2024 | 15831 | 0.100 |
Why?
|
| Neovascularization, Physiologic | 3 | 2014 | 1369 | 0.100 |
Why?
|
| Polymorphism, Genetic | 2 | 2014 | 4248 | 0.100 |
Why?
|
| Laser Therapy | 4 | 2002 | 1107 | 0.100 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2021 | 1085 | 0.100 |
Why?
|
| Mice, Mutant Strains | 2 | 2012 | 1752 | 0.100 |
Why?
|
| Graft Survival | 1 | 2023 | 3887 | 0.100 |
Why?
|
| RNA | 3 | 2014 | 2718 | 0.100 |
Why?
|
| Peptide Fragments | 2 | 2004 | 5151 | 0.100 |
Why?
|
| Combined Modality Therapy | 4 | 2011 | 8535 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2017 | 8637 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 2 | 2014 | 560 | 0.100 |
Why?
|
| Elastic Tissue | 2 | 2011 | 66 | 0.100 |
Why?
|
| Neuroprotective Agents | 2 | 2009 | 958 | 0.100 |
Why?
|
| Light | 2 | 2017 | 1358 | 0.100 |
Why?
|
| Mass Casualty Incidents | 1 | 2014 | 179 | 0.100 |
Why?
|
| Lens, Crystalline | 1 | 2014 | 387 | 0.100 |
Why?
|
| History, 21st Century | 2 | 2009 | 1572 | 0.100 |
Why?
|
| Risk Management | 1 | 2015 | 558 | 0.100 |
Why?
|
| Taurochenodeoxycholic Acid | 1 | 2011 | 35 | 0.100 |
Why?
|
| Goals | 1 | 2017 | 717 | 0.100 |
Why?
|
| Autoimmune Diseases | 3 | 2012 | 2256 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 2 | 2008 | 1613 | 0.090 |
Why?
|
| Caveolin 1 | 1 | 2013 | 255 | 0.090 |
Why?
|
| Metabolome | 1 | 2018 | 1009 | 0.090 |
Why?
|
| RNA, Neoplasm | 1 | 2014 | 748 | 0.090 |
Why?
|
| Light Coagulation | 1 | 2011 | 72 | 0.090 |
Why?
|
| Injections, Intravenous | 4 | 2003 | 1377 | 0.090 |
Why?
|
| Lipoproteins | 2 | 1997 | 879 | 0.090 |
Why?
|
| Macrophages, Peritoneal | 1 | 2012 | 244 | 0.090 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 3251 | 0.090 |
Why?
|
| Cell Count | 4 | 2015 | 1831 | 0.090 |
Why?
|
| Task Performance and Analysis | 1 | 2015 | 771 | 0.090 |
Why?
|
| Aluminum | 1 | 1991 | 150 | 0.090 |
Why?
|
| Leukostasis | 2 | 2009 | 23 | 0.090 |
Why?
|
| Corneal Diseases | 3 | 2024 | 535 | 0.090 |
Why?
|
| Endostatins | 2 | 2011 | 167 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2023 | 3447 | 0.090 |
Why?
|
| Biological Assay | 1 | 2014 | 627 | 0.090 |
Why?
|
| Microscopy, Confocal | 4 | 2019 | 1972 | 0.090 |
Why?
|
| Retinal Cone Photoreceptor Cells | 1 | 2012 | 183 | 0.090 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2011 | 101 | 0.090 |
Why?
|
| Arteriosclerosis | 1 | 1995 | 1055 | 0.090 |
Why?
|
| Genotype | 9 | 2014 | 13042 | 0.090 |
Why?
|
| Rhodamines | 1 | 2011 | 179 | 0.090 |
Why?
|
| Models, Animal | 3 | 2019 | 2120 | 0.090 |
Why?
|
| Mice, Knockout | 10 | 2019 | 14486 | 0.090 |
Why?
|
| Multiprotein Complexes | 1 | 2017 | 1110 | 0.090 |
Why?
|
| SEER Program | 1 | 2016 | 1444 | 0.090 |
Why?
|
| Quercetin | 1 | 2011 | 97 | 0.090 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 1 | 2010 | 34 | 0.090 |
Why?
|
| Blast Injuries | 1 | 2014 | 321 | 0.090 |
Why?
|
| Drug Substitution | 1 | 2013 | 291 | 0.090 |
Why?
|
| Aldehydes | 1 | 2011 | 170 | 0.090 |
Why?
|
| Diterpenes | 1 | 2011 | 169 | 0.090 |
Why?
|
| Lipopolysaccharides | 3 | 2016 | 2219 | 0.090 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2011 | 257 | 0.090 |
Why?
|
| Polyethylene Glycols | 1 | 2016 | 1196 | 0.090 |
Why?
|
| Induced Pluripotent Stem Cells | 2 | 2019 | 1888 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2017 | 2906 | 0.090 |
Why?
|
| DNA, Mitochondrial | 1 | 2015 | 872 | 0.090 |
Why?
|
| Protons | 2 | 2014 | 1114 | 0.080 |
Why?
|
| Ophthalmoscopy | 2 | 2008 | 172 | 0.080 |
Why?
|
| Capillary Leak Syndrome | 1 | 2009 | 34 | 0.080 |
Why?
|
| History, 20th Century | 2 | 2009 | 2766 | 0.080 |
Why?
|
| Adenylate Kinase | 1 | 2010 | 101 | 0.080 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2017 | 694 | 0.080 |
Why?
|
| Gene Expression | 6 | 2011 | 7597 | 0.080 |
Why?
|
| Incidence | 5 | 2024 | 21532 | 0.080 |
Why?
|
| Integrases | 1 | 2012 | 520 | 0.080 |
Why?
|
| Capillaries | 2 | 2024 | 756 | 0.080 |
Why?
|
| Anterior Eye Segment | 2 | 2009 | 144 | 0.080 |
Why?
|
| Integrin alpha4 | 1 | 2009 | 88 | 0.080 |
Why?
|
| Electroretinography | 3 | 2012 | 524 | 0.080 |
Why?
|
| Immunohistochemistry | 4 | 2019 | 11068 | 0.080 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2009 | 1656 | 0.080 |
Why?
|
| Salmonella typhimurium | 1 | 2011 | 348 | 0.080 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2011 | 348 | 0.080 |
Why?
|
| Interleukin-6 | 2 | 2017 | 3228 | 0.080 |
Why?
|
| Oculomotor Muscles | 2 | 2024 | 405 | 0.080 |
Why?
|
| Retinitis Pigmentosa | 1 | 2012 | 395 | 0.080 |
Why?
|
| Endocytosis | 1 | 2013 | 955 | 0.080 |
Why?
|
| Indocyanine Green | 3 | 2019 | 237 | 0.080 |
Why?
|
| Inpatients | 1 | 2020 | 2570 | 0.080 |
Why?
|
| Vitamins | 2 | 2009 | 1638 | 0.080 |
Why?
|
| Quality of Life | 3 | 2024 | 13489 | 0.080 |
Why?
|
| Young Adult | 10 | 2024 | 60048 | 0.080 |
Why?
|
| Microvessels | 2 | 2024 | 585 | 0.080 |
Why?
|
| NG-Nitroarginine Methyl Ester | 2 | 2007 | 262 | 0.080 |
Why?
|
| Interferon-alpha | 1 | 1993 | 910 | 0.080 |
Why?
|
| Nelfinavir | 1 | 2008 | 68 | 0.080 |
Why?
|
| Mice, Inbred DBA | 2 | 2006 | 624 | 0.080 |
Why?
|
| Infant, Newborn | 6 | 2024 | 26420 | 0.080 |
Why?
|
| Genes, Dominant | 1 | 2011 | 855 | 0.080 |
Why?
|
| Radiotherapy Dosage | 2 | 2014 | 2916 | 0.080 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2014 | 2061 | 0.080 |
Why?
|
| Cell Adhesion | 4 | 2009 | 3096 | 0.080 |
Why?
|
| Neoplasms | 3 | 2017 | 22365 | 0.080 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2006 | 5717 | 0.080 |
Why?
|
| Gene Expression Regulation | 4 | 2016 | 11930 | 0.070 |
Why?
|
| Massachusetts | 5 | 2018 | 8888 | 0.070 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2007 | 2884 | 0.070 |
Why?
|
| Mitochondrial Membranes | 1 | 2009 | 185 | 0.070 |
Why?
|
| Siblings | 3 | 2011 | 828 | 0.070 |
Why?
|
| Inflammation Mediators | 2 | 2014 | 1892 | 0.070 |
Why?
|
| Occupational Diseases | 1 | 1996 | 1457 | 0.070 |
Why?
|
| Interleukin-1beta | 2 | 2019 | 1027 | 0.070 |
Why?
|
| Collagen Type XVIII | 1 | 2007 | 52 | 0.070 |
Why?
|
| Caspase 8 | 2 | 2005 | 198 | 0.070 |
Why?
|
| Monocytes | 3 | 2023 | 2605 | 0.070 |
Why?
|
| Retinal Artery | 2 | 2000 | 109 | 0.070 |
Why?
|
| Fas Ligand Protein | 2 | 2005 | 216 | 0.070 |
Why?
|
| Polysaccharides | 1 | 2014 | 1024 | 0.070 |
Why?
|
| Injections, Intralesional | 1 | 2008 | 280 | 0.070 |
Why?
|
| Complement Activation | 2 | 2020 | 447 | 0.070 |
Why?
|
| Cell Membrane Permeability | 1 | 2009 | 571 | 0.070 |
Why?
|
| Collagen | 3 | 2019 | 2641 | 0.070 |
Why?
|
| Microscopy, Electron | 2 | 2012 | 2559 | 0.070 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 3269 | 0.070 |
Why?
|
| Nitric Oxide Donors | 1 | 2007 | 126 | 0.070 |
Why?
|
| Mice, Transgenic | 4 | 2018 | 9556 | 0.070 |
Why?
|
| Retinal Vasculitis | 1 | 2007 | 46 | 0.070 |
Why?
|
| Integrin alpha4beta1 | 1 | 2007 | 119 | 0.070 |
Why?
|
| Metformin | 1 | 2014 | 909 | 0.070 |
Why?
|
| Radiation Injuries | 1 | 2014 | 1198 | 0.070 |
Why?
|
| Smoking | 5 | 2023 | 9089 | 0.070 |
Why?
|
| Retreatment | 3 | 2011 | 598 | 0.070 |
Why?
|
| Cell Movement | 3 | 2008 | 5209 | 0.070 |
Why?
|
| Gliosis | 1 | 2007 | 246 | 0.070 |
Why?
|
| Lasers, Gas | 1 | 2008 | 104 | 0.070 |
Why?
|
| Immunity, Cellular | 1 | 2012 | 1561 | 0.070 |
Why?
|
| Tubercidin | 2 | 2017 | 14 | 0.070 |
Why?
|
| Carrier Proteins | 3 | 2015 | 4937 | 0.070 |
Why?
|
| Phenotype | 6 | 2018 | 16723 | 0.070 |
Why?
|
| Tissue Distribution | 3 | 2006 | 2299 | 0.070 |
Why?
|
| Macrophage-1 Antigen | 1 | 2007 | 286 | 0.060 |
Why?
|
| Flow Cytometry | 6 | 2014 | 5902 | 0.060 |
Why?
|
| Plasmids | 1 | 2011 | 2269 | 0.060 |
Why?
|
| Dipyridamole | 2 | 2017 | 143 | 0.060 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2008 | 352 | 0.060 |
Why?
|
| Alleles | 4 | 2011 | 6894 | 0.060 |
Why?
|
| Green Fluorescent Proteins | 1 | 2011 | 2065 | 0.060 |
Why?
|
| Lipoproteins, HDL | 1 | 2010 | 682 | 0.060 |
Why?
|
| Zinc | 1 | 2009 | 677 | 0.060 |
Why?
|
| Societies, Scientific | 1 | 2006 | 223 | 0.060 |
Why?
|
| Echinocandins | 1 | 2005 | 54 | 0.060 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2007 | 1942 | 0.060 |
Why?
|
| Florida | 1 | 2006 | 417 | 0.060 |
Why?
|
| Lipopeptides | 1 | 2005 | 71 | 0.060 |
Why?
|
| Bacteria | 1 | 2016 | 2216 | 0.060 |
Why?
|
| Receptors, Immunologic | 1 | 2011 | 1418 | 0.060 |
Why?
|
| Time Factors | 9 | 2021 | 40214 | 0.060 |
Why?
|
| Endothelium | 1 | 2008 | 768 | 0.060 |
Why?
|
| Models, Biological | 3 | 2011 | 9493 | 0.060 |
Why?
|
| Hot Temperature | 1 | 2011 | 1441 | 0.060 |
Why?
|
| Curriculum | 1 | 2018 | 3782 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 10 | 3 | 2011 | 275 | 0.060 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2014 | 1399 | 0.060 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2004 | 88 | 0.060 |
Why?
|
| Rupture | 1 | 2006 | 444 | 0.060 |
Why?
|
| Microspheres | 3 | 2008 | 788 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2007 | 582 | 0.060 |
Why?
|
| Eye Color | 1 | 2004 | 35 | 0.060 |
Why?
|
| Prevalence | 4 | 2024 | 15867 | 0.060 |
Why?
|
| Genetic Linkage | 1 | 2009 | 2342 | 0.060 |
Why?
|
| Congresses as Topic | 1 | 2009 | 812 | 0.060 |
Why?
|
| Animals, Genetically Modified | 1 | 2009 | 1564 | 0.060 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2009 | 777 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2007 | 751 | 0.060 |
Why?
|
| Signal Transduction | 7 | 2017 | 23642 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2015 | 2521 | 0.060 |
Why?
|
| Drug Combinations | 2 | 2019 | 2089 | 0.060 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 2420 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2020 | 9016 | 0.050 |
Why?
|
| Lens Implantation, Intraocular | 1 | 2005 | 192 | 0.050 |
Why?
|
| Matched-Pair Analysis | 1 | 2004 | 285 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 13000 | 0.050 |
Why?
|
| Boronic Acids | 1 | 2007 | 915 | 0.050 |
Why?
|
| Caspase 7 | 1 | 2003 | 51 | 0.050 |
Why?
|
| Membrane Proteins | 4 | 2007 | 7876 | 0.050 |
Why?
|
| Regional Blood Flow | 2 | 2024 | 1500 | 0.050 |
Why?
|
| DNA-Binding Proteins | 2 | 2017 | 9614 | 0.050 |
Why?
|
| Republic of Korea | 2 | 2016 | 591 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 627 | 0.050 |
Why?
|
| Gene Deletion | 2 | 2018 | 2673 | 0.050 |
Why?
|
| Coculture Techniques | 1 | 2007 | 1340 | 0.050 |
Why?
|
| Intubation | 1 | 2023 | 140 | 0.050 |
Why?
|
| Oligodendroglia | 1 | 2006 | 541 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2017 | 5799 | 0.050 |
Why?
|
| Phagocytosis | 2 | 2019 | 1530 | 0.050 |
Why?
|
| Retinopathy of Prematurity | 1 | 2007 | 450 | 0.050 |
Why?
|
| Blood Proteins | 1 | 2008 | 1191 | 0.050 |
Why?
|
| Emergency Medical Services | 1 | 2014 | 1947 | 0.050 |
Why?
|
| Greece | 2 | 2014 | 340 | 0.050 |
Why?
|
| Algorithms | 2 | 2020 | 14163 | 0.050 |
Why?
|
| Protein Binding | 2 | 2013 | 9343 | 0.050 |
Why?
|
| Switzerland | 1 | 2003 | 323 | 0.050 |
Why?
|
| Integrins | 1 | 2007 | 842 | 0.050 |
Why?
|
| Environment | 1 | 2008 | 1121 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 5887 | 0.050 |
Why?
|
| Anterior Chamber | 2 | 2014 | 194 | 0.050 |
Why?
|
| E-Selectin | 1 | 2004 | 577 | 0.050 |
Why?
|
| Gene Expression Profiling | 4 | 2011 | 9536 | 0.050 |
Why?
|
| Cytokines | 2 | 2014 | 7450 | 0.050 |
Why?
|
| Patient Selection | 1 | 2014 | 4258 | 0.050 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 1388 | 0.050 |
Why?
|
| Reoperation | 2 | 2022 | 4329 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2007 | 1335 | 0.050 |
Why?
|
| Drug Synergism | 2 | 2009 | 1760 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2011 | 1804 | 0.050 |
Why?
|
| Photolysis | 1 | 2001 | 94 | 0.050 |
Why?
|
| Immunophenotyping | 1 | 2006 | 1863 | 0.050 |
Why?
|
| Alcohol Drinking | 3 | 2018 | 4045 | 0.050 |
Why?
|
| Pyrazines | 1 | 2007 | 1205 | 0.050 |
Why?
|
| Radiotherapy | 2 | 2006 | 1501 | 0.050 |
Why?
|
| Bacterial Toxins | 1 | 2007 | 922 | 0.050 |
Why?
|
| Rose Bengal | 1 | 2002 | 115 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 12536 | 0.050 |
Why?
|
| Microscopy, Immunoelectron | 2 | 2014 | 316 | 0.050 |
Why?
|
| Databases, Genetic | 1 | 2008 | 1758 | 0.050 |
Why?
|
| DNA Primers | 4 | 2012 | 2827 | 0.050 |
Why?
|
| Hyperthermia, Induced | 1 | 2005 | 414 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2003 | 428 | 0.050 |
Why?
|
| Retinal Pigments | 1 | 2020 | 84 | 0.050 |
Why?
|
| Angiostatins | 1 | 2000 | 64 | 0.050 |
Why?
|
| Apolipoproteins E | 1 | 2007 | 1461 | 0.050 |
Why?
|
| Blotting, Northern | 3 | 1999 | 1550 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2017 | 1621 | 0.050 |
Why?
|
| Optic Nerve | 2 | 2006 | 571 | 0.050 |
Why?
|
| Transcription Factors | 2 | 2017 | 12165 | 0.040 |
Why?
|
| Molecular Weight | 2 | 2000 | 2173 | 0.040 |
Why?
|
| Epidemiologic Research Design | 1 | 2004 | 368 | 0.040 |
Why?
|
| Aging | 1 | 2019 | 8744 | 0.040 |
Why?
|
| Candidiasis | 1 | 2003 | 367 | 0.040 |
Why?
|
| Coumarins | 1 | 2000 | 119 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2016 | 3804 | 0.040 |
Why?
|
| Angioid Streaks | 1 | 2000 | 14 | 0.040 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2003 | 577 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2016 | 8082 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2005 | 1478 | 0.040 |
Why?
|
| Portugal | 1 | 2020 | 91 | 0.040 |
Why?
|
| Equipment Safety | 1 | 2001 | 250 | 0.040 |
Why?
|
| Recurrence | 3 | 2022 | 8507 | 0.040 |
Why?
|
| Atherosclerosis | 1 | 2016 | 3433 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2009 | 2256 | 0.040 |
Why?
|
| Longitudinal Studies | 3 | 2024 | 14783 | 0.040 |
Why?
|
| Histoplasmosis | 1 | 2000 | 63 | 0.040 |
Why?
|
| Neurodegenerative Diseases | 1 | 2009 | 1095 | 0.040 |
Why?
|
| Elastin | 2 | 2014 | 299 | 0.040 |
Why?
|
| Immunoprecipitation | 2 | 2014 | 874 | 0.040 |
Why?
|
| Cell Line, Tumor | 5 | 2017 | 17128 | 0.040 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2000 | 158 | 0.040 |
Why?
|
| Prognosis | 4 | 2016 | 29979 | 0.040 |
Why?
|
| Case-Control Studies | 6 | 2018 | 22287 | 0.040 |
Why?
|
| Coloring Agents | 2 | 2019 | 565 | 0.040 |
Why?
|
| Antineoplastic Agents | 3 | 2013 | 13658 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2007 | 1966 | 0.040 |
Why?
|
| Linkage Disequilibrium | 3 | 2008 | 1997 | 0.040 |
Why?
|
| Endothelin-1 | 1 | 2000 | 296 | 0.040 |
Why?
|
| Specialty Boards | 1 | 2020 | 235 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2011 | 4414 | 0.040 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2020 | 222 | 0.040 |
Why?
|
| Astrocytes | 1 | 2006 | 1351 | 0.040 |
Why?
|
| Diabetes Mellitus, Experimental | 3 | 2009 | 1124 | 0.040 |
Why?
|
| Receptors, Growth Factor | 1 | 1999 | 324 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2005 | 1505 | 0.040 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2000 | 1731 | 0.040 |
Why?
|
| Exocytosis | 1 | 2019 | 323 | 0.040 |
Why?
|
| Refraction, Ocular | 1 | 1999 | 188 | 0.040 |
Why?
|
| Laminin | 1 | 2019 | 405 | 0.040 |
Why?
|
| Rats, Inbred Lew | 2 | 2011 | 1162 | 0.040 |
Why?
|
| Age Distribution | 1 | 2024 | 2871 | 0.040 |
Why?
|
| Retinal Vein | 1 | 1997 | 47 | 0.040 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2019 | 3780 | 0.040 |
Why?
|
| Artifacts | 1 | 2006 | 1923 | 0.040 |
Why?
|
| Vitamin D | 1 | 2011 | 3311 | 0.040 |
Why?
|
| Cysteine-Rich Protein 61 | 1 | 2017 | 39 | 0.040 |
Why?
|
| Haplotypes | 3 | 2008 | 2722 | 0.040 |
Why?
|
| Decompression, Surgical | 1 | 2023 | 603 | 0.040 |
Why?
|
| National Eye Institute (U.S.) | 1 | 2017 | 5 | 0.040 |
Why?
|
| Heart Conduction System | 1 | 2003 | 1009 | 0.040 |
Why?
|
| Cell Membrane | 1 | 2007 | 3657 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 3 | 2014 | 6119 | 0.040 |
Why?
|
| Alu Elements | 1 | 2018 | 115 | 0.040 |
Why?
|
| Prosthesis Implantation | 1 | 2022 | 595 | 0.040 |
Why?
|
| Gene Frequency | 3 | 2009 | 3623 | 0.040 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2017 | 91 | 0.040 |
Why?
|
| Infusions, Intravenous | 2 | 1999 | 2227 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2021 | 1642 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2001 | 476 | 0.040 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 1997 | 142 | 0.040 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2003 | 1165 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2021 | 2473 | 0.030 |
Why?
|
| Suture Techniques | 1 | 2022 | 775 | 0.030 |
Why?
|
| Thioredoxin Reductase 2 | 1 | 2016 | 25 | 0.030 |
Why?
|
| Epoxide Hydrolases | 1 | 2017 | 122 | 0.030 |
Why?
|
| Cell Division | 2 | 2003 | 4473 | 0.030 |
Why?
|
| Ligands | 1 | 2004 | 3284 | 0.030 |
Why?
|
| Body Mass Index | 3 | 2018 | 13053 | 0.030 |
Why?
|
| Vasoconstrictor Agents | 1 | 2000 | 656 | 0.030 |
Why?
|
| Diet | 2 | 2020 | 8087 | 0.030 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2017 | 221 | 0.030 |
Why?
|
| T-Lymphocytes | 2 | 2012 | 10264 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2008 | 3858 | 0.030 |
Why?
|
| Educational Status | 1 | 2004 | 2515 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2019 | 809 | 0.030 |
Why?
|
| Aqueous Humor | 2 | 2011 | 152 | 0.030 |
Why?
|
| Smoking Cessation | 1 | 2008 | 2085 | 0.030 |
Why?
|
| Genetic Variation | 2 | 2010 | 6611 | 0.030 |
Why?
|
| Boston | 2 | 2014 | 9368 | 0.030 |
Why?
|
| Eye Enucleation | 2 | 2006 | 128 | 0.030 |
Why?
|
| Retinal Hemorrhage | 1 | 1996 | 98 | 0.030 |
Why?
|
| Angiography, Digital Subtraction | 1 | 1997 | 331 | 0.030 |
Why?
|
| Autoanalysis | 1 | 2015 | 70 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2017 | 4525 | 0.030 |
Why?
|
| RNA Interference | 2 | 2016 | 2830 | 0.030 |
Why?
|
| Autophagy | 2 | 2014 | 1349 | 0.030 |
Why?
|
| Ribonuclease III | 1 | 2018 | 271 | 0.030 |
Why?
|
| Adenosine | 1 | 2020 | 820 | 0.030 |
Why?
|
| Sensory Thresholds | 1 | 2017 | 377 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 2018 | 1065 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2023 | 1738 | 0.030 |
Why?
|
| Hyperoxia | 1 | 1997 | 259 | 0.030 |
Why?
|
| Polymers | 1 | 2003 | 1627 | 0.030 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 1997 | 271 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2006 | 2745 | 0.030 |
Why?
|
| Recombinant Proteins | 4 | 2007 | 6515 | 0.030 |
Why?
|
| Plasminogen Activators | 1 | 1995 | 199 | 0.030 |
Why?
|
| Mutation | 2 | 2011 | 30211 | 0.030 |
Why?
|
| Schools, Medical | 1 | 2021 | 882 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2023 | 9666 | 0.030 |
Why?
|
| Cattle | 1 | 2000 | 3819 | 0.030 |
Why?
|
| Vision, Ocular | 1 | 2018 | 458 | 0.030 |
Why?
|
| Verapamil | 1 | 1995 | 242 | 0.030 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2018 | 385 | 0.030 |
Why?
|
| Pregnancy Proteins | 1 | 1996 | 222 | 0.030 |
Why?
|
| Carotid Artery, Common | 1 | 1995 | 174 | 0.030 |
Why?
|
| DNA, Complementary | 2 | 2014 | 1989 | 0.030 |
Why?
|
| Nitric Oxide Synthase | 1 | 1997 | 911 | 0.030 |
Why?
|
| Biocompatible Materials | 1 | 2003 | 1702 | 0.030 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 1995 | 324 | 0.030 |
Why?
|
| Explosive Agents | 1 | 2014 | 26 | 0.030 |
Why?
|
| Nitroglycerin | 1 | 1995 | 332 | 0.030 |
Why?
|
| Severity of Illness Index | 3 | 2022 | 15944 | 0.030 |
Why?
|
| Lipoproteins, LDL | 1 | 2017 | 644 | 0.030 |
Why?
|
| Lysosomes | 1 | 2019 | 938 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2000 | 1405 | 0.030 |
Why?
|
| Bombs | 1 | 2014 | 73 | 0.030 |
Why?
|
| Pregnancy | 1 | 2016 | 30260 | 0.030 |
Why?
|
| Neuropilin-1 | 1 | 2014 | 91 | 0.030 |
Why?
|
| Arachidonic Acids | 1 | 2014 | 296 | 0.030 |
Why?
|
| Superoxide Dismutase | 1 | 2016 | 596 | 0.030 |
Why?
|
| Drug Carriers | 4 | 2003 | 708 | 0.030 |
Why?
|
| Imidazoles | 1 | 2019 | 1168 | 0.030 |
Why?
|
| Evoked Potentials, Visual | 1 | 2016 | 418 | 0.030 |
Why?
|
| Information Storage and Retrieval | 1 | 2019 | 830 | 0.030 |
Why?
|
| Fibrinolytic Agents | 1 | 2003 | 2080 | 0.030 |
Why?
|
| Crystallization | 1 | 2014 | 520 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2023 | 2381 | 0.030 |
Why?
|
| Texas | 1 | 2014 | 410 | 0.030 |
Why?
|
| Antigens, CD | 2 | 2015 | 4035 | 0.030 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 6 | 1 | 2012 | 27 | 0.030 |
Why?
|
| Cohort Studies | 4 | 2023 | 41749 | 0.030 |
Why?
|
| Uvea | 1 | 2012 | 31 | 0.030 |
Why?
|
| Oxidants | 1 | 2013 | 168 | 0.030 |
Why?
|
| Career Choice | 1 | 2019 | 769 | 0.030 |
Why?
|
| Edema | 1 | 1996 | 765 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2020 | 12252 | 0.030 |
Why?
|
| Triamcinolone Acetonide | 1 | 2013 | 105 | 0.020 |
Why?
|
| Cardiovascular Diseases | 2 | 2011 | 15660 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2017 | 1074 | 0.020 |
Why?
|
| Energy Intake | 1 | 2020 | 2145 | 0.020 |
Why?
|
| Tropoelastin | 1 | 2011 | 28 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2020 | 2001 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2017 | 998 | 0.020 |
Why?
|
| Catheterization, Peripheral | 1 | 1995 | 347 | 0.020 |
Why?
|
| Sulfones | 1 | 2014 | 448 | 0.020 |
Why?
|
| S Phase | 1 | 2013 | 424 | 0.020 |
Why?
|
| Retinal Dystrophies | 1 | 2012 | 65 | 0.020 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 1996 | 925 | 0.020 |
Why?
|
| PPAR gamma | 1 | 2014 | 485 | 0.020 |
Why?
|
| Random Allocation | 1 | 1996 | 2396 | 0.020 |
Why?
|
| Membranes | 1 | 2011 | 164 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2003 | 2764 | 0.020 |
Why?
|
| Peptides | 1 | 2003 | 4354 | 0.020 |
Why?
|
| Neutrophils | 1 | 2023 | 3786 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 1995 | 990 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2018 | 9384 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2001 | 2336 | 0.020 |
Why?
|
| Postoperative Period | 1 | 1996 | 1826 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2003 | 3966 | 0.020 |
Why?
|
| Chromosome Mapping | 2 | 2010 | 4618 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2012 | 687 | 0.020 |
Why?
|
| Complement Factor I | 1 | 2010 | 14 | 0.020 |
Why?
|
| Albumins | 1 | 2013 | 577 | 0.020 |
Why?
|
| Cyclins | 1 | 2013 | 605 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2014 | 996 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2017 | 2202 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2011 | 283 | 0.020 |
Why?
|
| Thrombospondin 1 | 1 | 2011 | 257 | 0.020 |
Why?
|
| Sex Factors | 1 | 2004 | 10627 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 3231 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 1999 | 1679 | 0.020 |
Why?
|
| Base Sequence | 3 | 2008 | 12418 | 0.020 |
Why?
|
| Oxidoreductases | 1 | 2012 | 410 | 0.020 |
Why?
|
| Regression Analysis | 2 | 2010 | 6339 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2013 | 740 | 0.020 |
Why?
|
| Benchmarking | 1 | 2016 | 1057 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 1605 | 0.020 |
Why?
|
| Epistasis, Genetic | 1 | 2011 | 353 | 0.020 |
Why?
|
| Stents | 1 | 2021 | 3195 | 0.020 |
Why?
|
| Biotinylation | 1 | 2009 | 185 | 0.020 |
Why?
|
| Panophthalmitis | 1 | 1989 | 6 | 0.020 |
Why?
|
| Endothelium, Corneal | 1 | 1991 | 212 | 0.020 |
Why?
|
| Cinnamates | 1 | 2009 | 59 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2014 | 1083 | 0.020 |
Why?
|
| Receptors, Calcitriol | 1 | 2011 | 361 | 0.020 |
Why?
|
| Clinical Trials as Topic | 2 | 2003 | 8052 | 0.020 |
Why?
|
| Nitriles | 1 | 2014 | 980 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 2014 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2006 | 11665 | 0.020 |
Why?
|
| Bromodeoxyuridine | 1 | 2009 | 310 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2011 | 858 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2013 | 1688 | 0.020 |
Why?
|
| Acute Disease | 2 | 2013 | 7241 | 0.020 |
Why?
|
| Hypoglycemic Agents | 2 | 2012 | 3108 | 0.020 |
Why?
|
| Evans Blue | 1 | 2008 | 42 | 0.020 |
Why?
|
| Monocyte Chemoattractant Proteins | 1 | 2008 | 48 | 0.020 |
Why?
|
| Formazans | 1 | 2007 | 8 | 0.020 |
Why?
|
| Epidemiologic Studies | 1 | 2011 | 677 | 0.020 |
Why?
|
| Tetrazolium Salts | 1 | 2007 | 92 | 0.020 |
Why?
|
| Aprotinin | 1 | 2008 | 94 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2014 | 1197 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2017 | 4289 | 0.020 |
Why?
|
| Histidine | 1 | 2008 | 301 | 0.020 |
Why?
|
| Pichia | 1 | 2007 | 49 | 0.020 |
Why?
|
| Fluoresceins | 1 | 2007 | 235 | 0.020 |
Why?
|
| Atrophy | 1 | 2012 | 1646 | 0.020 |
Why?
|
| Indicators and Reagents | 1 | 2007 | 456 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 2863 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 3428 | 0.020 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2008 | 174 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2009 | 753 | 0.020 |
Why?
|
| Life Style | 1 | 2018 | 3932 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2013 | 3620 | 0.020 |
Why?
|
| Acetylation | 1 | 2009 | 1055 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2009 | 483 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2008 | 515 | 0.020 |
Why?
|
| Neoplasm Proteins | 2 | 2009 | 3601 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2007 | 2889 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2014 | 3609 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2014 | 1930 | 0.020 |
Why?
|
| COS Cells | 1 | 2007 | 1135 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2023 | 5520 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2007 | 784 | 0.020 |
Why?
|
| Matrix Metalloproteinases | 1 | 2008 | 393 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2011 | 2227 | 0.020 |
Why?
|
| P-Selectin | 1 | 2008 | 598 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 6231 | 0.020 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2005 | 46 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2017 | 3703 | 0.020 |
Why?
|
| Corneal Transplantation | 1 | 1989 | 315 | 0.010 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2005 | 58 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2006 | 24314 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 12075 | 0.010 |
Why?
|
| Molecular Epidemiology | 1 | 2007 | 473 | 0.010 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2007 | 693 | 0.010 |
Why?
|
| Hypercholesterolemia | 1 | 2011 | 1145 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2011 | 2731 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2017 | 4063 | 0.010 |
Why?
|
| Orbital Neoplasms | 1 | 2006 | 223 | 0.010 |
Why?
|
| Nanoparticles | 1 | 2016 | 1983 | 0.010 |
Why?
|
| Tyrosine | 1 | 2008 | 1427 | 0.010 |
Why?
|
| In Situ Hybridization | 2 | 1999 | 1892 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2012 | 6228 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2001 | 7445 | 0.010 |
Why?
|
| Demography | 1 | 2008 | 1641 | 0.010 |
Why?
|
| Logistic Models | 1 | 2018 | 13289 | 0.010 |
Why?
|
| Calibration | 1 | 2006 | 819 | 0.010 |
Why?
|
| Comorbidity | 1 | 2018 | 10590 | 0.010 |
Why?
|
| Corynebacterium Infections | 1 | 2003 | 27 | 0.010 |
Why?
|
| Reference Values | 1 | 2010 | 4938 | 0.010 |
Why?
|
| Azacitidine | 1 | 2005 | 336 | 0.010 |
Why?
|
| Amphotericin B | 1 | 2003 | 143 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2004 | 10396 | 0.010 |
Why?
|
| Fluconazole | 1 | 2003 | 156 | 0.010 |
Why?
|
| Circular Dichroism | 1 | 2003 | 337 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2005 | 897 | 0.010 |
Why?
|
| Exons | 1 | 2008 | 2393 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1996 | 6004 | 0.010 |
Why?
|
| Predictive Value of Tests | 2 | 2011 | 15442 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2009 | 2234 | 0.010 |
Why?
|
| Chlorophyllides | 1 | 2002 | 54 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 2003 | 424 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2003 | 11519 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2003 | 564 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2007 | 2923 | 0.010 |
Why?
|
| Diffusion Chambers, Culture | 1 | 2000 | 49 | 0.010 |
Why?
|
| Reproducibility of Results | 2 | 2010 | 20218 | 0.010 |
Why?
|
| Gene Targeting | 1 | 2003 | 841 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2003 | 1375 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 3798 | 0.010 |
Why?
|
| Histones | 1 | 2009 | 2600 | 0.010 |
Why?
|
| Double-Blind Method | 2 | 2003 | 12464 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2003 | 1715 | 0.010 |
Why?
|
| Family | 1 | 2009 | 3210 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2009 | 2953 | 0.010 |
Why?
|
| Risk | 1 | 2010 | 9609 | 0.010 |
Why?
|
| Equipment Design | 1 | 2006 | 3522 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2003 | 2678 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2011 | 8740 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 5798 | 0.010 |
Why?
|
| Coronary Circulation | 1 | 2003 | 1617 | 0.010 |
Why?
|
| Peroxidase | 1 | 2000 | 610 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2008 | 4785 | 0.010 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1996 | 205 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 14718 | 0.010 |
Why?
|
| Trabecular Meshwork | 1 | 1996 | 101 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 1996 | 284 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 2006 | 1661 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1996 | 775 | 0.010 |
Why?
|
| Fluoroimmunoassay | 1 | 1994 | 30 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 4857 | 0.010 |
Why?
|
| Factor VIII | 1 | 1996 | 349 | 0.010 |
Why?
|
| Staphylococcal Infections | 1 | 2003 | 1398 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2008 | 3532 | 0.010 |
Why?
|
| Macaca mulatta | 1 | 1999 | 2363 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 36742 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 1997 | 1880 | 0.010 |
Why?
|
| Coronary Angiography | 1 | 2003 | 4541 | 0.010 |
Why?
|
| Hypertension | 1 | 2011 | 8616 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 1996 | 1104 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1996 | 4168 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 12795 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1999 | 8120 | 0.000 |
Why?
|
| Oxygen | 1 | 1997 | 4269 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1996 | 13420 | 0.000 |
Why?
|
| Streptococcal Infections | 1 | 1989 | 618 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1996 | 17617 | 0.000 |
Why?
|